TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 517996

Group type: EXPERIMENTAL
Intervention: Intermittent tourniquet release with 5 seconds deflation (group I)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intermittent tourniquet release with 30 seconds deflation (group II)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tourniquet released at once (group III)
Number of subjects: 25
Study: 30969452

Group type: EXPERIMENTAL
Intervention: Taking joint pain medication
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: More education
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Better ability to cope economically
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Ability to cope economically
Number of subjects: 1294
Study: 27329923

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with House Dust Mite allergen extract
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25728723

Group type: EXPERIMENTAL
Intervention: Home-delivered DASH/SRD-compliant meals
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual dietary advice
Number of subjects: 66
Study: 23376799

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine, clevudine)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues
Number of subjects: 124
Study: 21992121

Group type: EXPERIMENTAL
Intervention: BIBF 1120 150 mg twice a day
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study: 19784512

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dexa)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ondansetron (Onda)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dexamethasone + Ondansetron (Dexa+Onda)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (Cont)
Number of subjects: 77
Study: 17116064

Group type: EXPERIMENTAL
Intervention: Timing of placental delivery at 20 minutes
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Timing of placental delivery at 30 minutes
Number of subjects: 1607
Study: 12457048

Group type: EXPERIMENTAL
Intervention: Hospital alert system for hospital staff
Number of subjects: 606

Group type: COMPARATOR
Intervention: GP alert system for community general practitioners
Number of subjects: 606
Study: 10767815

Group type: EXPERIMENTAL
Intervention: Early vigorous medical exercise therapy (8-week active rehabilitation program with vigorous lumbar stabilizing exercises)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (mild program of 2 to 3 back exercises at home after 2 months of rest)
Number of subjects: 63
Study: 9370387

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diltiazem CD 300 mg daily
Number of subjects: 16
Study: 8459956

Group type: EXPERIMENTAL
Intervention: Immediate postpartum curettage
Number of subjects: 32

Group type: COMPARATOR
Intervention: No curettage (Control)
Number of subjects: 32
Study: 3943266

Group type: EXPERIMENTAL
Intervention: Lanoxin (0.5 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lanoxicaps (0.4 mg)
Number of subjects: 13
Study: 30923022

Group type: EXPERIMENTAL
Intervention: Text messages targeted to primary care patients and tailored to quit readiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-week supply of nicotine patches and/or lozenges (NRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both text messaging and NRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief advice only
Number of subjects: 0
Study: 29277895

Group type: EXPERIMENTAL
Intervention: Enzalutamide (ENZ) and CCX771 (CXCR7 inhibitor) combination treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Enzalutamide (ENZ)
Number of subjects: 2

Group type: COMPARATOR
Intervention: CCX771 (CXCR7 inhibitor)
Number of subjects: 2
Study: 25403681

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Abatacept (for those who achieved complete response)
Number of subjects: 134
Study: 22447495

Group type: EXPERIMENTAL
Intervention: CT-D (Cognitive Therapy targeting overestimations of danger)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CT-R (Cognitive Therapy targeting inflated beliefs of personal responsibility)
Number of subjects: 78
Study: 20735804

Group type: EXPERIMENTAL
Intervention: Selenium sulfide shampoo 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ciclopirox shampoo 1%
Number of subjects: 40
Study: 16896962

Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 54
Study: 15022148

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 1841

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1841
Study: 11787924

Group type: COMPARATOR
Intervention: Transdermal 17‐beta oestradiol 50 microg/day for 21 days (cyclical therapy)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Continuous transdermal 17‐beta oestradiol 50 microg/day
Number of subjects: 2
Study: 9480174

Group type: EXPERIMENTAL
Intervention: Insulin dependent diabetes mellitus (IDDM)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Non insulin dependent diabetes mellitus (NIDDM)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (non diabetic patients with ischaemic heart disease)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 67
Study: 8320575

Group type: COMPARATOR
Intervention: Routine computer reminders (control)
Number of subjects: 5407

Group type: EXPERIMENTAL
Intervention: Required to circle one of four responses to computer reminders
Number of subjects: 5407
Study: 3624124

Group type: EXPERIMENTAL
Intervention: 30% O2
Number of subjects: 6

Group type: COMPARATOR
Intervention: Air
Number of subjects: 6
Study: 31431080

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided percutaneous microwave ablation
Number of subjects: 32

Group type: COMPARATOR
Intervention: No oxytocin (control)
Number of subjects: 32
Study: 29970818

Group type: EXPERIMENTAL
Intervention: New method for planning coverage paths for fixed-wing UAVs that accounts for wind and decomposes regions into convex polygons.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous coverage path planning techniques without wind consideration.
Number of subjects: 0
Study: 27533305

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoglycemic intravenous glucose infusion (IIGI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IIGI with glucagon infusion (0.8 ng/kg/min from 0 to 25 minutes)
Number of subjects: 20
Study: 24857100

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin/paclitaxel X 5 and 41.4 Gy concurrent radiotherapy followed by surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 21332855

Group type: EXPERIMENTAL
Intervention: Cryotherapy with ice in a plastic bag (3 sessions of 10 minutes each over 3 hours)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No cryotherapy (control group)
Number of subjects: 59
Study: 20975104

Group type: EXPERIMENTAL
Intervention: High-molecular-weight (HMW) carbohydrate solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight (LMW) carbohydrate solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: Flavored water (WAT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Comparison between HMW and LMW solutions
Number of subjects: 6
Study: 17953788

Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) 2g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) 5g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) 10g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) 15g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) (all doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Citrulline (CIT) (15g)
Number of subjects: 8
Study: 16514811

Group type: EXPERIMENTAL
Intervention: Allicor (a long‐acting garlic drug) for 12 months
Number of subjects: 167
Study: 14690159

Group type: EXPERIMENTAL
Intervention: Clodronate 1500 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Clodronate 900 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Pamidronate 90 mg
Number of subjects: 63
Study: 11778280

Group type: EXPERIMENTAL
Intervention: HLF regimen (hydroxycamptothecin HCPT/leucovorin LV/fluorouracil 5‐Fu)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ELF regimen (etoposide VP‐16/LV/5‐Fu)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HLF regimen
Number of subjects: 48
Study: 9059473

Group type: EXPERIMENTAL
Intervention: Regular inhaled salbutamol for four weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20058472

Group type: EXPERIMENTAL
Intervention: Alligator plate fixation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wire fixation (cerclage)
Number of subjects: 17
Study: 3571097

Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate (LCHO) 45 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Solid carbohydrate confectionery bar (SCHO) 45 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-CHO meal (200 g) + Solid carbohydrate confectionery bar (M + SCHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study: 30453477

Group type: EXPERIMENTAL
Intervention: Daily tryptophan intake
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Daily protein intake
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Daily energy intake
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Serum transthyretin (TTR)
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Serum insulin-like growth factor-1 (IGF-1)
Number of subjects: 873
Study: 27391450

Group type: EXPERIMENTAL
Intervention: Experimental tree monocultures and secondary forests
Number of subjects: 0
Study: 25403703

Group type: EXPERIMENTAL
Intervention: Distal coronary sinus pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right atrial appendage pacing
Number of subjects: 0
Study: 22963997

Group type: EXPERIMENTAL
Intervention: Brief pulse ECT
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ultrabrief pulse ECT
Number of subjects: 150
Study: 20653695

Group type: EXPERIMENTAL
Intervention: nebicapone 150 mg
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: entacapone 200 mg (active control)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: nebicapone 50 mg
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: nebicapone 100 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 252
Study: 18372941

Group type: EXPERIMENTAL
Intervention: Fibre enriched semi-skimmed milk (20 grams of soluble fibre per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Semi-skimmed milk (control group)
Number of subjects: 32
Study: 16332468

Group type: EXPERIMENTAL
Intervention: Behavioral feedback intervention
Number of subjects: 161

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 161
Study: 11151264

Group type: EXPERIMENTAL
Intervention: Topical nonpreserved steroids for 2 weeks followed by punctal occlusion
Number of subjects: 30
Study: 8656364

Group type: EXPERIMENTAL
Intervention: Pressure patching after application of antibiotic/steroid ointment (A/S)
Number of subjects: 41

Group type: COMPARATOR
Intervention: A/S ointment twice a day without patching
Number of subjects: 41
Study: 1290331

Group type: EXPERIMENTAL
Intervention: Lo-Estrin (norethindrone acetate 1.5 mg plus ethinyl estradiol 0.030 mg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Lo-Femenal (norgestrel 0.30 mg plus ethinyl estradiol 0.030 mg)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lo-Estrin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Lo-Femenal
Number of subjects: 148
Study: 6721124

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg orally the night before operation and 1 mg on the morning of operation)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Pentobarbital (100 mg orally the night before operation) + Atropine (0.01 mg/kg intramuscular) + Pethidine (1 mg/kg intramuscular on the morning of operation)
Number of subjects: 68
Study: 30421439

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 585

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585
Study: 28639539

Group type: EXPERIMENTAL
Intervention: Male circumcision as an HIV prevention strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histo-immunological studies of the foreskin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contextual differences in HIV transmission patterns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conflicting scientific details regarding foreskin's susceptibility to HIV
Number of subjects: 0
Study: 25535980

Group type: EXPERIMENTAL
Intervention: Bio-Oss
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Osseous
Number of subjects: 20
Study: 22627778

Group type: EXPERIMENTAL
Intervention: Telephone brief intervention (BI)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 249
Study: 21784372

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 34
Study: 19514077

Group type: EXPERIMENTAL
Intervention: MIBG scintigraphy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Abnormal AFT in PD
Number of subjects: 39

Group type: COMPARATOR
Intervention: Abnormal AFT in MSA-p
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Early and delayed H/M ratio
Number of subjects: 39
Study: 16675212

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination (SFC) 50/250 microg one inhalation twice daily (bid)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Formoterol/budesonide combination (FBC) 6/200 microg two inhalations bid
Number of subjects: 1391
Study: 14702457

Group type: EXPERIMENTAL
Intervention: Cygnus GlucoWatch biographer
Number of subjects: 45
Study: 11379681

Group type: COMPARATOR
Intervention: Sevoflurane with 0% xenon (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 20% xenon (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 40% xenon (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% xenon (Group 4)
Number of subjects: 60
Study: 9226601

Group type: EXPERIMENTAL
Intervention: LHRH‐A
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15449510

Group type: EXPERIMENTAL
Intervention: 25 mg hyaluronate/2.5 ml (verum)
Number of subjects: 209

Group type: COMPARATOR
Intervention: 0.25 mg hyaluronate/2.5 ml (control)
Number of subjects: 209
Study: 3029790

Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 800 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31590686

Group type: EXPERIMENTAL
Intervention: Pharmacies recruitment strategy
Number of subjects: 4013

Group type: EXPERIMENTAL
Intervention: Paid media recruitment strategy
Number of subjects: 4013

Group type: EXPERIMENTAL
Intervention: Word of mouth recruitment strategy
Number of subjects: 4013

Group type: EXPERIMENTAL
Intervention: Unpaid media recruitment strategy
Number of subjects: 4013

Group type: EXPERIMENTAL
Intervention: Seniors outreach recruitment strategy
Number of subjects: 4013

Group type: EXPERIMENTAL
Intervention: Health care providers recruitment strategy
Number of subjects: 4013

Group type: EXPERIMENTAL
Intervention: Media strategies
Number of subjects: 4013
Study: 28664755

Group type: EXPERIMENTAL
Intervention: N‐LPA intervention using a tri‐axial accelerometer
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: LPA intervention
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: N‐LPA intervention
Number of subjects: 38
Study: 24923986

Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) 7.5 g/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22995543

Group type: EXPERIMENTAL
Intervention: Group PF (2 mg/kg propofol+1 mcg/kg fentanyl)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group P (2 mg/kg propofol alone)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group PMF (2 mg/kg propofol+1 mcg/kg fentanyl+0.02 mg/kg midazolam)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group E (0.2 mg/kg etomidate alone)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group EF (0.2 mg/kg etomidate+1 mcg/kg fentanyl)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group EMF (0.2 mg/kg etomidate+1 mcg/kg fentanyl+0.02 mg/kg midazolam)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Propofol groups (P, PF, PMF)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Etomidate groups (E, EF, EMF)
Number of subjects: 240
Study: 22321279

Group type: EXPERIMENTAL
Intervention: tolvaptan 15 - 60 mg daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study: 19950759

Group type: EXPERIMENTAL
Intervention: Bio-calcium from shells Pinctada maxima (260 mg of elemental calcium, three times a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inorganic CaCO3 (500 mg daily)
Number of subjects: 50
Study: 17101637

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) present at discharge with ischaemic heart disease
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) present at discharge without ischaemic heart disease
Number of subjects: 3587

Group type: COMPARATOR
Intervention: Patients without atrial fibrillation (AF)
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 3587
Study: 15353386

Group type: EXPERIMENTAL
Intervention: Recruitment strategy from professional sources (e.g., community agencies)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Recruitment strategy from non-professional sources (e.g., health fairs)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Recruitment strategy from advertisements
Number of subjects: 310
Study: 12136614

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic agents (mainly amiodarone)
Number of subjects: 0
Study: 9534006

Group type: EXPERIMENTAL
Intervention: Oscillations of cytoplasmic Ca2+ concentration [(Ca2+]i) in beta cells; specific dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin secretion; specific dosage and duration not available.
Number of subjects: 0
Study: 7698624

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily) and Amoxicillin (1 g twice daily) for 2 weeks (Group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Omeprazole (40 mg daily) alone for 2 weeks (Group B)
Number of subjects: 51
Study: 2541754

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 793305

Group type: EXPERIMENTAL
Intervention: Lithium citrate (Litarex)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lithium sulphate (Lithionit Durettes)
Number of subjects: 18
Study: 30558758

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Optimized medical therapy (OMT)
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Propensity score-matched CABG
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Propensity score-matched PCI
Number of subjects: 1104
Study: 27813225

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound (US) performed immediately before surgery by a radiologist accompanied by the surgeon.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no preoperative ultrasound).
Number of subjects: 154
Study: 25880052

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg three times a day for 3 days before operation
Number of subjects: 178
Study: 23996340

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg/day) for 4 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg/day) for 8 weeks
Number of subjects: 69
Study: 21093496

Group type: EXPERIMENTAL
Intervention: MV+DTP+OPV
Number of subjects: 568

Group type: COMPARATOR
Intervention: MV+OPV
Number of subjects: 568
Study: 19407472

Group type: EXPERIMENTAL
Intervention: WGHFB (government funding and family support)
Number of subjects: 71

Group type: COMPARATOR
Intervention: WGHFA (self-financed care)
Number of subjects: 71
Study: 17445902

Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09% (Xibrom)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 15064599

Group type: COMPARATOR
Intervention: High carbohydrate meal (HC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moderate fat meal (MF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (HC) and Moderate fat meal (MF)
Number of subjects: 24
Study: 11254817

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (budesonide, beclomethasone dipropionate)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 374

Group type: COMPARATOR
Intervention: Non-corticosteroid treatment (reference group)
Number of subjects: 374
Study: 9881085

Group type: EXPERIMENTAL
Intervention: D10 Group (10 mg dexamethasone)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: D20 Group (20 mg dexamethasone)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: D2 Group (not specified dexamethasone dosage)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 44
Study: 8024942

Group type: EXPERIMENTAL
Intervention: Culturally similar video (CSV) AIDS education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culturally dissimilar video (CDV) AIDS education
Number of subjects: 0
Study: 28960244

Group type: EXPERIMENTAL
Intervention: Case-only approach for measuring markers predicting treatment effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers measured in cases only
Number of subjects: 0